ArticleFrontiers in endocrinology2025
Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictors of prolonged hypogonadism in men with prolactinomas despite biochemical remission: the role of baseline luteinizing hormone.Journal of endocrinological investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To evaluate the prevalence of pituitary hormone deficiencies in patients with prolactinomas, identify clinical and radiological predictors of non-gonadal hypopituitarism at diagnosis, and evaluate the potential for pituitary function recovery over long-term follow-up. Methods: We conducted a retrospective multicenter study including 145 patients with prolactinomas diagnosed between 2000 and 2024 at two tertiary centers. All anterior pituitary axes were evaluated at diagnosis and during follow-up. Results: At diagnosis, 54 of 145 patients (37.2%) had at least one pituitary hormone deficiency. Hypogonadism was the most common deficit (34.5%), followed by non-gonadal hypopituitarism in 14.5%, including secondary adrenal insufficiency: 8.3%, central hypothyroidism: 7.6%, growth hormone deficiency (GHD): 6.9%. Macroadenomas were significantly more prevalent than microadenomas (25.8% vs. 2.7%, p<0.001). Tumor size was the only independent predictor of non-gonadal hypopituitarism at diagnosis (OR: 1.1, 95%CI: 1.03-1.20; p=0.007). ROC analysis identified 17 mm as the optimal cut-off to predict non-gonadal pituitary hormone deficiencies at diagnosis (sensitivity 84%, specificity 77%, AUC = 0.836). During follow-up (median 70 months), 66.7% of patients recovered at least one pituitary axis, with higher recovery in microadenomas (100% vs. 63.0%, p=0.038). Tumor size remained the strongest predictor of recovery (OR: 0.56, 95%CI: 0.34-0.94; p=0.029). Conclusions: Non-gonadal hypopituitarism is common in prolactinomas, especially larger tumors. Tumor size was the strongest predictor of both the presence and recovery of hormonal deficits, with an optimal cut-off of 17 mm. Long-term follow-up is essential, as many patients, especially those with smaller tumors, recover pituitary function after treatment, with gonadal and adrenal axes showing the highest likelihood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.